Solesence, Inc. (SLSN) AI Stock Analysis

Solesence, Inc., formerly known as Nanophase Technologies Corporation, provides engineered materials, formulation development, and commercial manufacturing services in the United States. It manufactures surface engineered zinc oxide and titanium dioxide ingredients, as well as skin care formulations featuring mineral-based UV protection enabled by proprietary active pharmaceutical ingredients. The company also produces skin health products, such as sunscreens and daily care products, serving the beauty, wellness, and skin health sectors. Beyond personal care, its products are sold into medical diagnostics, architectural coatings, industrial coatings, abrasion-resistant additives, and plastics additives applications.

Between FY2021 and FY2025, revenue expanded at a 4-year compound annual growth rate of 20.5%, rising from $29.5M in FY2021 to $62.1M in FY2025. Annual profitability has fluctuated, with net income moving from -$2.6M in FY2022 and -$4.4M in FY2023 to $4.2M in FY2024 and $1.8M in FY2025. Gross margin was 25.8% in FY2025, down from 30.9% in FY2024. For the trailing twelve months, revenue totaled $55.4M with an operating margin of 0.8% and a net profit margin of -5.2%. In the quarter ended June 30, 2026, revenue fell 24.7% year-over-year, and quarterly earnings dropped 93.5%.

As of June 30, 2026, Solesence held $1.0M in cash and short-term investments against total debt of $22.7M, resulting in net debt of $21.7M. The company's current ratio stood at 0.97, and its debt-to-equity ratio was 1.73 against shareholders' equity of $13.2M. For FY2025, operating cash flow was -$8.6M and capital expenditures were $2.1M, leading to free cash flow of -$10.7M. Over the past five years, the company's share count increased 50.3%.

Solesence carries a market capitalization of $63.6M and an enterprise value of $79.6M. Its forward P/E multiple is 11.4x, below the median of 14.3x for its US-listed Consumer Defensive peers. However, the company trades at an EV to EBITDA ratio of 27.7x, compared to the peer median of 11.7x, and a price-to-sales ratio of 1.1x versus the peer median of 0.7x. Over the past year, the stock fell 77.0%, underperforming the S&P 500 return of 16.8%. Year-to-date through October 16, 2026, the stock has declined 43.8%.

Consensus rating distributions and price targets are not reported for Solesence. Over the trailing twelve months, the company recorded an EPS of -$0.04. Performance in the latest reported quarter ended June 30, 2026 showed a quarterly earnings contraction of 93.5% year-over-year. The company's next earnings report is scheduled for November 10, 2026.

This page is an AI-written research summary of Solesence, Inc. (SLSN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SLSN income statement, SLSN balance sheet, SLSN key metrics, SLSN chart. See the SLSN stock overview for the latest quote and news.